

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OCT 1 1 2007

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

Sheet	1	of	5
-------	---	----	---

**Complete if Known**

<i>Application Number</i>	10/556,220
<i>Filing Date</i>	May 7, 2004
<i>First Named Inventor</i>	Craig B. Thompson
<i>Art Unit</i>	1614
<i>Examiner Name</i>	To Be Determined
<i>Attorney Docket Number</i>	UPN0012-100

[illegible][illegible]

**Examiner  
Signature**

Date Considered

\*EXAMINER: Initia! if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CR/



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 5

**Complete if Known**

Application Number	10/556,220
Filing Date	May 7, 2004
First Named Inventor	Craig B. Thompson
Art Unit	1614
Examiner Name	To Be Determined
Attorney Docket Number	UPN0012-100

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AF	Barth, C., et al "Inhibition of cholesterol synthesis by (-)-hydroxycitrate in perfused rat liver. Evidence for an extramitochondrial mevalonate synthesis from acetyl coenzyme A," <i>FEBS LETT.</i> (1972) 22(3):343-346.	
	AG	Benjamin, W.B., et al. "ATP citrate-lyase and glycogen synthase kinase-3 beta in 3T3-L1 cells during differentiation into adipocytes." <i>Biochem J.</i> (1994) 300( Pt 2):477-482.	
	AH	Berkhout, T.A., et al. "The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2," <i>Biochem J.</i> (1990) 272(1):181-6.	
	AI	Berwick, D.C., et al. "The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes," <i>J. Biol Chem</i> (2002) 277(37):33895-900.	
	AJ	Borgelt et al., "The palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group." <i>Int J. Radiat Oncol Biol Phys</i> (1980) 6(1):1-9.	
	AK	Czernin, J. "Clinical applications of FDG-PET in oncology." <i>Acta Medica Austriaca</i> (2002) 29(5):162-70.	
	AL	Dolle, R.E., "ATP-citrate lyase as a target for hypolipidemic intervention. Sulfoximine and 3-hydroxy-beta-lactam containing analogues of citric acid as potential tight-binding inhibitors," <i>J. Med Chem.</i> (1992) 35(26):4875-4884.	
	AM	Dolle, R.E., et al. "Synthesis of novel thiol-containing citric acid analogues. Kinetic evaluation of these and other potential active-site-directed and mechanism-based inhibitors of ATP citrate lyase," <i>J. Med Chem.</i> (1995) 38(3):537-543.	
	AN	Elshourbagy, N. A., et al "Rat ATP citrate-lyase. Molecular cloning and sequence analysis of a full-length cDNA and mRNA abundance as a function of diet, organ, and age," <i>J. Biol Chem</i> (1990) 265(3):1430-435.	
	AO	Elshourbagy, N.A., et al. "Cloning and expression of a human ATP-citrate lyase Cdna," <i>Eur J Biochem.</i> (1992) 204(2):491-499.	
	AP	Fang, M. et al., "Citrate and the conversion of carbohydrate into fat. The regulation of fatty acid synthesis by rat liver extracts," <i>Biochem J.</i> ( 1967) 105(2):803-11.	
	AQ	Frauwirth, K.A., et al., "The CD28 signaling pathway regulates glucose metabolism," <i>Immunity</i> (2002) 16(6):769-777.	
	AR	Fukuda, H. et al. "Regulation of ATP citrate-lyase gene expression in hepatocytes and adipocytes in normal and genetically obese rats." <i>J. Biochem (Tokyo)</i> (1999) 126(2):437-444.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CR/



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 5

**Complete if Known**

Application Number	10/556,220
Filing Date	May 7, 2004
First Named Inventor	Craig B. Thompson
Art Unit	1614
Examiner Name	To Be Determined
Attorney Docket Number	UPN0012-100

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AS	Gribble, A. D., et al. "ATP-citrate lyase as a target for hypolipidemic intervention. Design and synthesis of 2-substituted butanedioic acids as novel, potent inhibitors of the enzyme." <i>J. Med. Chem.</i> (1996) 39(18):3569-3584.	
	AT	Gribble, A.D., et al. "ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo." <i>J. Med Chem.</i> (1998) 41(19):3582-3595.	
	AU	Hoffman GE, et al. "Properties and organ distribution of ATP citrate (pro-3S)-lyase." <i>Biochim Biophys Acta</i> (1980) 620(1):151-8	
	AV	Inoue, H., et al. "Dietary response of the hepatic citrate-cleavage enzyme in hypophysectomized rats" <i>J Biol Chem.</i> , 60:93-5, 1966.	
	AW	Barrow, CJ, et al. "Antimycins, inhibitors of ATP-citrate lyase, from a <i>Streptomyces</i> sp," <i>Journal of Antibiotics</i> , (1997) 50(9):729-33	
	AX	Kaplan et al, "Purification and characterization of the reconstitutively active tricarboxylate transporter from rat liver mitochondria." <i>J. Biol Chem.</i> (1990) 265(22):13379-85.	
	AY	Law D et al. "Citrate transport in proximal cell line," <i>Am J. Physiol</i> (1992) 263(1 Pt 1):C220-5.	
	AZ	Lowenstein, J. M. "Effect of (-)-hydroxycitrate on fatty acid synthesis by rat liver in vivo." <i>J Biol Chem</i> , (1971) 246(3):629-32.	
	BA	Morikawa, J., et al., "Molecular cloning of novel mouse and human putative citrate lyase beta-subunit." <i>Biochem Biophys Res Commun</i> (2001) 289(5):1282-6.	
	BB	Paradies G. et al., "Enhanced activity of the tricarboxylate carrier and modification of lipids in hepatic mitochondria from hyperthyroid rats," <i>Arch Biochem Biophys</i> (1990) 278(2):425-30	
	BC	Pearce, N. J., et al., "The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076." <i>Biochem J</i> (1998) 334 (Pt 1):113-9.	
	BD	Plas, D. R., et al., "Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology," <i>J Biol. Chem.</i> (2001) 276(15):12041-8.	
	BE	Saxty, B. A., et al., "Synthesis and evaluation of (+) and (-)-2,2-difluorocitrate as inhibitors of rat-liver ATP-citrate lyase and porcine-heart aconitase," <i>Eur J. Biochem.</i> (1991) 202(3):889-96.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CR/



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 5

**Complete if Known**

Application Number	10/556,220
Filing Date	May 7, 2004
First Named Inventor	Craig B. Thompson
Art Unit	1614
Examiner Name	To Be Determined
Attorney Docket Number	UPN0012-100

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BF	Simpson J.R., et al "Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials." <i>Int J. Radiat Oncol Biol Phys</i> (1993) 26(2):239-44.	
	BC	Stipani, I et al. "Purification of the active mitochondrial tricarboxylate carrier by hydroxylapatite chromatography." <i>FEBS Lett</i> (1983) 161(2):269-74.	
	BH	Sullivan, A. C., et al "Effect of (-)-hydroxycitrate upon the accumulation of lipid in the rat. II. Appetite." <i>Lipids</i> (1974) 9(2):129-34.	
	BI	Sullivan, A. C., et al. "Effect of (-)-hydroxycitrate upon the accumulation of lipid in the rat. I. Lipogenesis." <i>Lipids</i> (1974) 9(2):121-8.	
	BJ	Sullivan AC, et al. "Reactivity and inhibitor potential of hydroxycitrate isomers with citrate synthase, citrate lyase, and ATP citrate lyase." <i>J Biol Chem</i> (1977) 252(21):7583-90.	
	BK	Sullivan, A. C., "(--)-threo-Chlorocitric acid: a novel anorectic agent." <i>Pharmacol Biochem Behav</i> , (1981) 15(2):303-10.	
	BL	Szutowicz A., et al., "Effect of (-)-hydroxycitrate on the activities of ATP citrate lyase and the enzymes of acetyl-CoA metabolism in rat brain," <i>Acta Biochim Pol</i> (1976) 23(2-3):227-34.	
	BM	Vander Heiden, M. G., et al., "Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria." <i>Cell</i> , (1997) 91(5):627-37.	
	BN	Vander Heiden, M. G., et al., "Growth factors can influence cell growth and survival through effects on glucose metabolism." <i>Mol Cell Biol</i> (2001) 21(17):5899-5912.	
	BO	Warburg and Negelein, [Uber das Absorptionsspektrum des Atmungsforments], <i>Biochemische Zeitschrift</i> (1929), 214, 64-100.	
	BP	Watson, J. A., et al. "Citrate and the conversion of carbohydrate into fat. Fatty acid synthesis by a combination of cytoplasm and mitochondria." <i>J. Biol Chem</i> , (1970) 245(22):5993-6002.	
	BQ	Zara V et al., "Purification and characterization of the tricarboxylate carrier from eel liver mitochondria," <i>Biochem Biophys Res Commun</i> (1996) 223(3):508-13.	
	*BR	Perez et al., <i>Principles and Practice of Radiation Oncology</i> , 2 <sup>nd</sup> Ed, JB Kippincott Co, Phila (1992).	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CR/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Application Number</i>	10/556,220
				<i>Filing Date</i>	May 7, 2004
				<i>First Named Inventor</i>	Craig B. Thompson
				<i>Art Unit</i>	1614
				<i>Examiner Name</i>	To Be Determined
				<i>Attorney Docket Number</i>	UPN0012-100
(Use as many sheets as necessary)					
Sheet	5	of	5		

[illegible]

Examiner Signature	/Charlesworth Rae/	Date Considered	01/29/2009
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CR/